A rosszindulatú daganatok gyógyszeres terápiájának irányelvei

a citosztatikumok hatékonyságának feltételei.

Translated title of the contribution: Principles of drug therapy of malignant tumors: determinants of the efficacy of cytostatic agents

A. Jeney, J. Kralovánszky

Research output: Contribution to journalArticle

Abstract

Successful therapy with the anticancer cytostatic agents are remarkably dependent on the appropriate dosage and schedules of the treatment. To this end however it is highly important to have insights into the tumorbiological, pharmacokinetics, pharmacobiochemical and molecular-biological factors which underline the efficacy of the cytostatic agents. The present communication intend to provide a comprehensive survey for the medical doctors attending cancer patients concerning the mode of action of those anti tumour agents traditionally classified as alkylating agents, antimetabolites, topoisomerase inhibitors, and antimitotic agents. It will be emphasized that the currently available agents show no specific action on the malignant cells because they are inhibitors of cell proliferation and target certain molecular mechanism implicated in the cell cycle. The basis for the relatively selective antitumour action are rather different for the various cytostatic agents, nevertheless the differential activation and also the repair capacity in the tumour and in the normal organs offer an explanation for the agents acting directly or indirectly on DNA. Knowledge of the mode of action of the cytostatic agents offer not only a better understanding for their therapeutic failure but gives guidelines for those tumorbiological features which are necessary for their efficacy. In the last years substantial data have accumulated which indicate the possibility to improve the therapeutic action by modulating the pharmacokinetic or the pharmacobiochemical determinants of the antitumour drug action.

Original languageHungarian
Pages (from-to)1339-1345
Number of pages7
JournalOrvosi Hetilap
Volume140
Issue number24
Publication statusPublished - Jun 13 1999

Fingerprint

Cytostatic Agents
Drug Therapy
Antineoplastic Agents
Neoplasms
Pharmacokinetics
Topoisomerase Inhibitors
Antimitotic Agents
Antimetabolites
Alkylating Agents
Biological Factors
Therapeutics
Appointments and Schedules
Cell Cycle
Cell Proliferation
Guidelines
DNA

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A rosszindulatú daganatok gyógyszeres terápiájának irányelvei : a citosztatikumok hatékonyságának feltételei. / Jeney, A.; Kralovánszky, J.

In: Orvosi Hetilap, Vol. 140, No. 24, 13.06.1999, p. 1339-1345.

Research output: Contribution to journalArticle

@article{777d82e03c6c4b89934353e44ef1de98,
title = "A rosszindulat{\'u} daganatok gy{\'o}gyszeres ter{\'a}pi{\'a}j{\'a}nak ir{\'a}nyelvei: a citosztatikumok hat{\'e}konys{\'a}g{\'a}nak felt{\'e}telei.",
abstract = "Successful therapy with the anticancer cytostatic agents are remarkably dependent on the appropriate dosage and schedules of the treatment. To this end however it is highly important to have insights into the tumorbiological, pharmacokinetics, pharmacobiochemical and molecular-biological factors which underline the efficacy of the cytostatic agents. The present communication intend to provide a comprehensive survey for the medical doctors attending cancer patients concerning the mode of action of those anti tumour agents traditionally classified as alkylating agents, antimetabolites, topoisomerase inhibitors, and antimitotic agents. It will be emphasized that the currently available agents show no specific action on the malignant cells because they are inhibitors of cell proliferation and target certain molecular mechanism implicated in the cell cycle. The basis for the relatively selective antitumour action are rather different for the various cytostatic agents, nevertheless the differential activation and also the repair capacity in the tumour and in the normal organs offer an explanation for the agents acting directly or indirectly on DNA. Knowledge of the mode of action of the cytostatic agents offer not only a better understanding for their therapeutic failure but gives guidelines for those tumorbiological features which are necessary for their efficacy. In the last years substantial data have accumulated which indicate the possibility to improve the therapeutic action by modulating the pharmacokinetic or the pharmacobiochemical determinants of the antitumour drug action.",
author = "A. Jeney and J. Kralov{\'a}nszky",
year = "1999",
month = "6",
day = "13",
language = "Hungarian",
volume = "140",
pages = "1339--1345",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "24",

}

TY - JOUR

T1 - A rosszindulatú daganatok gyógyszeres terápiájának irányelvei

T2 - a citosztatikumok hatékonyságának feltételei.

AU - Jeney, A.

AU - Kralovánszky, J.

PY - 1999/6/13

Y1 - 1999/6/13

N2 - Successful therapy with the anticancer cytostatic agents are remarkably dependent on the appropriate dosage and schedules of the treatment. To this end however it is highly important to have insights into the tumorbiological, pharmacokinetics, pharmacobiochemical and molecular-biological factors which underline the efficacy of the cytostatic agents. The present communication intend to provide a comprehensive survey for the medical doctors attending cancer patients concerning the mode of action of those anti tumour agents traditionally classified as alkylating agents, antimetabolites, topoisomerase inhibitors, and antimitotic agents. It will be emphasized that the currently available agents show no specific action on the malignant cells because they are inhibitors of cell proliferation and target certain molecular mechanism implicated in the cell cycle. The basis for the relatively selective antitumour action are rather different for the various cytostatic agents, nevertheless the differential activation and also the repair capacity in the tumour and in the normal organs offer an explanation for the agents acting directly or indirectly on DNA. Knowledge of the mode of action of the cytostatic agents offer not only a better understanding for their therapeutic failure but gives guidelines for those tumorbiological features which are necessary for their efficacy. In the last years substantial data have accumulated which indicate the possibility to improve the therapeutic action by modulating the pharmacokinetic or the pharmacobiochemical determinants of the antitumour drug action.

AB - Successful therapy with the anticancer cytostatic agents are remarkably dependent on the appropriate dosage and schedules of the treatment. To this end however it is highly important to have insights into the tumorbiological, pharmacokinetics, pharmacobiochemical and molecular-biological factors which underline the efficacy of the cytostatic agents. The present communication intend to provide a comprehensive survey for the medical doctors attending cancer patients concerning the mode of action of those anti tumour agents traditionally classified as alkylating agents, antimetabolites, topoisomerase inhibitors, and antimitotic agents. It will be emphasized that the currently available agents show no specific action on the malignant cells because they are inhibitors of cell proliferation and target certain molecular mechanism implicated in the cell cycle. The basis for the relatively selective antitumour action are rather different for the various cytostatic agents, nevertheless the differential activation and also the repair capacity in the tumour and in the normal organs offer an explanation for the agents acting directly or indirectly on DNA. Knowledge of the mode of action of the cytostatic agents offer not only a better understanding for their therapeutic failure but gives guidelines for those tumorbiological features which are necessary for their efficacy. In the last years substantial data have accumulated which indicate the possibility to improve the therapeutic action by modulating the pharmacokinetic or the pharmacobiochemical determinants of the antitumour drug action.

UR - http://www.scopus.com/inward/record.url?scp=0033551409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033551409&partnerID=8YFLogxK

M3 - Article

VL - 140

SP - 1339

EP - 1345

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 24

ER -